Cargando…

Protection from neuropathy in extreme duration type 1 diabetes

A proportion of individuals with type 1 diabetes mellitus for more than 50 years (medallists) may be protected from developing nephropathy, retinopathy and neuropathy. Detailed neuropathy phenotyping was undertaken in a cohort of 33 medallists aged 63.7 ± 1.4 years with diabetes for 58.5 ± 0.8 years...

Descripción completa

Detalles Bibliográficos
Autores principales: Azmi, Shazli, Ferdousi, Maryam, Kalteniece, Alise, Petropoulos, Ioannis N., Ponirakis, Georgios, Alam, Uazman, Asghar, Omar, Marshall, Andrew, Sankar, Adhithya, Boulton, Andrew J. M., Soran, Handrean, Efron, Nathan, Malik, Rayaz A.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Wiley Periodicals, Inc. 2020
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7983958/
https://www.ncbi.nlm.nih.gov/pubmed/33236478
http://dx.doi.org/10.1111/jns.12423
_version_ 1783667973654839296
author Azmi, Shazli
Ferdousi, Maryam
Kalteniece, Alise
Petropoulos, Ioannis N.
Ponirakis, Georgios
Alam, Uazman
Asghar, Omar
Marshall, Andrew
Sankar, Adhithya
Boulton, Andrew J. M.
Soran, Handrean
Efron, Nathan
Malik, Rayaz A.
author_facet Azmi, Shazli
Ferdousi, Maryam
Kalteniece, Alise
Petropoulos, Ioannis N.
Ponirakis, Georgios
Alam, Uazman
Asghar, Omar
Marshall, Andrew
Sankar, Adhithya
Boulton, Andrew J. M.
Soran, Handrean
Efron, Nathan
Malik, Rayaz A.
author_sort Azmi, Shazli
collection PubMed
description A proportion of individuals with type 1 diabetes mellitus for more than 50 years (medallists) may be protected from developing nephropathy, retinopathy and neuropathy. Detailed neuropathy phenotyping was undertaken in a cohort of 33 medallists aged 63.7 ± 1.4 years with diabetes for 58.5 ± 0.8 years and HbA1c of 65.9 ± 2.1 mmol/mmol. Medallists had a significantly higher HbA1c (P < .001), lower estimated glomerular filtration rate (eGFR) (P = .005) and higher albumin creatinine excretion ratio (ACR) (P = .01), but a lower total cholesterol (P < .001), triacylglycerols (P = .001), low density lipoprotein‐cholesterol (P < .001) and higher high density lipoprotein‐cholesterol (P = .03), compared to controls. Twenty‐four percent of participants were identified as “escapers” without confirmed diabetic neuropathy. They had a lower neuropathy symptom profile (P = .002), vibration perception threshold (P = .02), warm threshold (P = .05), higher peroneal amplitude (P = .005), nerve conduction velocity (P = .03), heart rate variability (P = .001), corneal nerve fibre density (P = 0.001), branch density (P < .001) and length (P = .001), compared to medallists with diabetic neuropathy. Escapers had a shorter duration of diabetes (P = .006), lower alcohol consumption (P = .04), lower total cholesterol (P = .04) and LDL (P = .02), higher eGFR (P = .001) and lower ACR (P < .001). Patients with extreme duration diabetes without diabetic neuropathy have a comparable HbA1c, blood pressure and body mass index, but a more favourable lipid profile and consume less alcohol compared to those with diabetic neuropathy.
format Online
Article
Text
id pubmed-7983958
institution National Center for Biotechnology Information
language English
publishDate 2020
publisher Wiley Periodicals, Inc.
record_format MEDLINE/PubMed
spelling pubmed-79839582021-03-24 Protection from neuropathy in extreme duration type 1 diabetes Azmi, Shazli Ferdousi, Maryam Kalteniece, Alise Petropoulos, Ioannis N. Ponirakis, Georgios Alam, Uazman Asghar, Omar Marshall, Andrew Sankar, Adhithya Boulton, Andrew J. M. Soran, Handrean Efron, Nathan Malik, Rayaz A. J Peripher Nerv Syst Research Reports A proportion of individuals with type 1 diabetes mellitus for more than 50 years (medallists) may be protected from developing nephropathy, retinopathy and neuropathy. Detailed neuropathy phenotyping was undertaken in a cohort of 33 medallists aged 63.7 ± 1.4 years with diabetes for 58.5 ± 0.8 years and HbA1c of 65.9 ± 2.1 mmol/mmol. Medallists had a significantly higher HbA1c (P < .001), lower estimated glomerular filtration rate (eGFR) (P = .005) and higher albumin creatinine excretion ratio (ACR) (P = .01), but a lower total cholesterol (P < .001), triacylglycerols (P = .001), low density lipoprotein‐cholesterol (P < .001) and higher high density lipoprotein‐cholesterol (P = .03), compared to controls. Twenty‐four percent of participants were identified as “escapers” without confirmed diabetic neuropathy. They had a lower neuropathy symptom profile (P = .002), vibration perception threshold (P = .02), warm threshold (P = .05), higher peroneal amplitude (P = .005), nerve conduction velocity (P = .03), heart rate variability (P = .001), corneal nerve fibre density (P = 0.001), branch density (P < .001) and length (P = .001), compared to medallists with diabetic neuropathy. Escapers had a shorter duration of diabetes (P = .006), lower alcohol consumption (P = .04), lower total cholesterol (P = .04) and LDL (P = .02), higher eGFR (P = .001) and lower ACR (P < .001). Patients with extreme duration diabetes without diabetic neuropathy have a comparable HbA1c, blood pressure and body mass index, but a more favourable lipid profile and consume less alcohol compared to those with diabetic neuropathy. Wiley Periodicals, Inc. 2020-12-04 2021-03 /pmc/articles/PMC7983958/ /pubmed/33236478 http://dx.doi.org/10.1111/jns.12423 Text en © 2020 The Authors. Journal of the Peripheral Nervous System published by Wiley Periodicals LLC on behalf of Peripheral Nerve Society. This is an open access article under the terms of the http://creativecommons.org/licenses/by-nc-nd/4.0/ License, which permits use and distribution in any medium, provided the original work is properly cited, the use is non‐commercial and no modifications or adaptations are made.
spellingShingle Research Reports
Azmi, Shazli
Ferdousi, Maryam
Kalteniece, Alise
Petropoulos, Ioannis N.
Ponirakis, Georgios
Alam, Uazman
Asghar, Omar
Marshall, Andrew
Sankar, Adhithya
Boulton, Andrew J. M.
Soran, Handrean
Efron, Nathan
Malik, Rayaz A.
Protection from neuropathy in extreme duration type 1 diabetes
title Protection from neuropathy in extreme duration type 1 diabetes
title_full Protection from neuropathy in extreme duration type 1 diabetes
title_fullStr Protection from neuropathy in extreme duration type 1 diabetes
title_full_unstemmed Protection from neuropathy in extreme duration type 1 diabetes
title_short Protection from neuropathy in extreme duration type 1 diabetes
title_sort protection from neuropathy in extreme duration type 1 diabetes
topic Research Reports
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7983958/
https://www.ncbi.nlm.nih.gov/pubmed/33236478
http://dx.doi.org/10.1111/jns.12423
work_keys_str_mv AT azmishazli protectionfromneuropathyinextremedurationtype1diabetes
AT ferdousimaryam protectionfromneuropathyinextremedurationtype1diabetes
AT kalteniecealise protectionfromneuropathyinextremedurationtype1diabetes
AT petropoulosioannisn protectionfromneuropathyinextremedurationtype1diabetes
AT ponirakisgeorgios protectionfromneuropathyinextremedurationtype1diabetes
AT alamuazman protectionfromneuropathyinextremedurationtype1diabetes
AT asgharomar protectionfromneuropathyinextremedurationtype1diabetes
AT marshallandrew protectionfromneuropathyinextremedurationtype1diabetes
AT sankaradhithya protectionfromneuropathyinextremedurationtype1diabetes
AT boultonandrewjm protectionfromneuropathyinextremedurationtype1diabetes
AT soranhandrean protectionfromneuropathyinextremedurationtype1diabetes
AT efronnathan protectionfromneuropathyinextremedurationtype1diabetes
AT malikrayaza protectionfromneuropathyinextremedurationtype1diabetes